In a randomized phase III trial of cabozantinib vs. everolimus in advanced RCC (METEOR), VEGF, sVEGFR2, IL-8, CA9, HGF, MET, GAS6, and AXL were assessed as biomarkers in plasma of 621 randomized patients [133]. Here, HGF is linked to renal cell carcinoma.